Pfizer (PFE) acquires exclusive rights to commercialise obesity therapy in China and is to pay Hangzhou Sciwind Biosciences up to USD 495mln
Newsquawk Staff ·
Pfizer (PFE) acquires exclusive rights to commercialise obesity therapy in China and is to pay Hangzhou Sciwind Biosciences up to USD 495mln.
What it means
Pfizer's acquisition of exclusive rights to commercialize an obesity therapy in China for up to USD 495 million indicates a strategic expansion into a rapidly growing market. This deal not only enhances Pfizer's product portfolio but could also signal increased competition in the obesity treatment sector, potentially impacting peer valuations and market dynamics in the broader pharmaceuticals space.
- Senior US Treasury trade official Eric Ettorre will leave to join Netflix (NFLX), reports Axios
- Ukrainian President Zelensky says negotiations between Ukraine, Russia and the US could take place as early as November 10th
- US Midterms (6 days out): Florida flips to a Republican early-vote lead and Kansas narrows further; Crystal Ball shifts House and Senate races towards Democrats
- Israeli election results show Netanyahu's bloc with 53 seats, Eisenkot's bloc with 47 and Arab parties with 19, following the counting of all votes excluding double-envelope ballots, i24 reports
- Atomic Energy Organization of Iran Spokesman says protocol for building small reactors with Russia is being finalized
Related headlines
- Al-Mayadeen correspondent in Iran says Iranian officials believe that Trump wants to bring the nuclear issue into the negotiations, which Iran rejects1 hour ago
- Russian Deputy PM Novak says they are open to work with US partners on energy, but there are no current discussions around a return to specific projects4 hours ago
- US EQUITY OPEN: Indices rangebound ahead of FOMC and major earnings59 min ago
- Amphenol (APH) Q3 2026 (USD): Adj. EPS 0.80 (exp. 0.73), Sales 10.2bln (exp. 9.49bln)3 hours ago
- GE Vernova (GEV) expects USD 50-100mln of annual cost synergies from Trench by 2030, according to the conference call3 hours ago
- Etsy Inc. (ETSY) Q3 2026 (USD): EPS 1.00 (exp. 0.77), Revenue 692mln (exp. 668mln)3 hours ago
- Garmin Ltd. (GRMN) Q3 2026 (USD): Adj. EPS 2.76 (exp. 2.41), Revenue 1.99bln (exp. 1.99bln)4 hours ago
- Phillips 66 (PSX) Q3 2026 (USD): Adj. EPS 14.08 (exp. 11.73)4 hours ago
- Aon (AON) Q3 (USD): Adj. EPS 3.36 (exp. 3.30), Revenue 4.1bln (exp. 4.08bln)4 hours ago
- Daily US Conference Calendar - 28th October 2026: JNJ, BA, CAT3 hours ago
- UK DMO says gross gilt issuance planned for 2026/27 is GBP 250.6bln (exp. 249.6bln, prev. 246.2bln in April remit)1 hour ago
- Eli Lilly’s (LLY) retatrutide delivered greater A1C reduction and more than double the weight loss of Novo Nordisk’s (NOVOB DC) Ozempic at its highest approved dose in head-to-head trial4 hours ago
- Automatic Data Processing (ADP) Q3 2026 (USD): Adj. EPS 2.82 (exp. 2.77), Revenue 5.5bln (exp. 5.48bln). FY revenue growth view of 6%, adj. EPS growth view of 10-12% 4 hours ago
- JPMorgan Chase (JPM) reportedly faces an additional GBP 100-150mln tax bill following the UK government's decision to double the corporation tax surcharge on banks, potentially jeopardising plans for its new London headquarters, Sky News reports44 min ago
- T-Mobile (TMUS) CEO to step down from the board2 hours ago